Experienced in Juvenile Idiopathic Arthritis (JIA)

Dr. Charles A. Birbara

Rheumatology
25 Oak Ave, 
Worcester, MA 
Experienced in Juvenile Idiopathic Arthritis (JIA)
25 Oak Ave, 
Worcester, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Charles Birbara is a Rheumatologist in Worcester, Massachusetts. Dr. Birbara is rated as an Experienced provider by MediFind in the treatment of Juvenile Idiopathic Arthritis (JIA). His top areas of expertise are Psoriatic Arthritis, Psoriasis, Bursitis, and Tenosynovitis.

His clinical research consists of co-authoring 8 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Rheumatology
Licenses
Specialist in MA
Hospital Affiliations
Umass Memorial Medical Center/university Campus
Umass Memorial Healthalliance Hospitals
Umass Memorial Health - Harrington Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health New England
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

25 Oak Ave, Worcester, MA 01605

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: October 12, 2023
Intervention Type: Drug
Study Drugs: Olokizumab, Methotrexate
Study Phase: Phase 3
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Drug: Olokizumab
Study Phase: Phase 3
A Phase IIb, Randomized, Double-blind Study in Subjects With Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared With Placebo in Subjects With an Inadequate Response to Methotrexate
A Phase IIb, Randomized, Double-blind Study in Subjects With Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared With Placebo in Subjects With an Inadequate Response to Methotrexate
Enrollment Status: Completed
Publish Date: September 28, 2020
Intervention Type: Drug
Study Phase: Phase 2
Lyme Test Indication Combinations (LyTIC) Study
Lyme Test Indication Combinations (LyTIC) Study
Enrollment Status: Terminated
Publish Date: December 13, 2018
Intervention Type: Diagnostic test
View 4 Less Clinical Trials

8 Total Publications

Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.
Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.
Journal: RMD open
Published: February 16, 2018
Similar Doctors
Elite in Juvenile Idiopathic Arthritis (JIA)
Dr. Peter A. Nigrovic
Rheumatology | Pediatric Rheumatology | Pediatrics
Elite in Juvenile Idiopathic Arthritis (JIA)
Dr. Peter A. Nigrovic
Rheumatology | Pediatric Rheumatology | Pediatrics

Brigham And Womens Physicians Organization Inc

75 Francis St, 
Boston, MA 
 (35.4 miles away)
617-732-5500
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Peter Nigrovic is a Rheumatologist and a Pediatric Rheumatologist in Boston, Massachusetts. Dr. Nigrovic is rated as a Distinguished provider by MediFind in the treatment of Juvenile Idiopathic Arthritis (JIA). His top areas of expertise are Juvenile Idiopathic Arthritis (JIA), Arthritis, Rheumatoid Arthritis (RA), and Systemic Lupus Erythematosus (SLE). Dr. Nigrovic is currently accepting new patients.

Elite in Juvenile Idiopathic Arthritis (JIA)
Dr. Olha Halyabar
Pediatric Rheumatology | Rheumatology
Elite in Juvenile Idiopathic Arthritis (JIA)
Dr. Olha Halyabar
Pediatric Rheumatology | Rheumatology
300 Longwood Ave, 
Boston, MA 
 (35.5 miles away)
617-355-6000
Languages Spoken:
English
See accepted insurances

Olha Halyabar is a Pediatric Rheumatologist and a Rheumatologist in Boston, Massachusetts. Dr. Halyabar is rated as a Distinguished provider by MediFind in the treatment of Juvenile Idiopathic Arthritis (JIA). Her top areas of expertise are Juvenile Idiopathic Arthritis (JIA), Kawasaki Disease, Mevalonate Kinase Deficiency, and Ehlers-Danlos Syndrome (EDS).

Elite in Juvenile Idiopathic Arthritis (JIA)
Dr. Mindy S. Lo
Pediatric Rheumatology | Pediatrics | Rheumatology
Elite in Juvenile Idiopathic Arthritis (JIA)
Dr. Mindy S. Lo
Pediatric Rheumatology | Pediatrics | Rheumatology

Children's Hospital Pediatric Associates, Inc

300 Longwood Ave, 
Boston, MA 
 (35.5 miles away)
617-355-6000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mindy Lo is a Pediatric Rheumatologist and a Pediatrics provider in Boston, Massachusetts. Dr. Lo is rated as a Distinguished provider by MediFind in the treatment of Juvenile Idiopathic Arthritis (JIA). Her top areas of expertise are Juvenile Idiopathic Arthritis (JIA), Kawasaki Disease, Juvenile Dermatomyositis, and Vasculitis. Dr. Lo is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Birbara's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile